FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s supplemental Biologics License Application (sBLA) seeking...
Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug status for BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure...
Emergent BioSolutions Reports First Quarter 2016 Financial Results
Q1 2016 financial performance in line with guidance. CDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on October 1, 2016. In transitioning to the follow-on...
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks...
Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 5, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2016, recent business...
Emergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for Triple-Negative Breast Cancer
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its bispecific ADAPTIRTM (modular protein technology) molecule, ES425, at the American Association for...
Emergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in Building 55
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the...
Emergent BioSolutions Announces Filing of Form 10 Registration Statement for Its Planned Spin-Off of Its Biosciences Business Aptevo Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission in connection with the company's...
Emergent BioSolutions to Participate in Needham & Company’s 15th Annual Healthcare Conference in April 2016
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in Needham & Company’s 15th Annual Healthcare Conference, April 12-13,...
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2015 Financial Results and Reaffirms 2016 Outlook
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31,...
Emergent BioSolutions’ Emergard Auto-Injector Platform for Nerve Agent Antidote Delivery Selected by U.S. Department of Defense and Battelle for Testing and Development
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Emergard™, the company’s ruggedized, military-grade auto-injector platform, has been selected by the U.S. Department of Defense (DoD)...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve...